Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07349537 · ClinicalTrials.gov registry record · Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 574
- Enrollment target
- 5
- Study locations
NCT07349537: Recruiting Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, sponsored by Revolution Medicines.
NCT07349537 is a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 574 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (47% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07349537, a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 574 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Primary Outcome
Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5
Conditions Studied
Interventions
- DRUG RMC-5127
- DRUG daraxonrasib
- DRUG cetuximab
Study Locations (5)
Texas
- NEXT - Dallas - Dallas
- NEXT - San Antonio
- START - San Antonio - San Antonio
Michigan
- START Midwest - Grand Rapids
Virginia
- NEXT - Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 574 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
What NCT07349537 shows while recruiting
NCT07349537 is an interventional study that assigns participants to a tested intervention. The registered 574 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (47% higher).
The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which RMC-5127 is the first listed.
NCT07349537 lists 5 locations in 3 states (Texas, Michigan, Virginia).
Frequently Asked Questions
What is clinical trial NCT07349537 about?
NCT07349537 is a clinical study titled "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
What is the current status of trial NCT07349537?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 574 participants. The study started on 2026-01-08. Estimated completion is 2028-10.
What conditions does trial NCT07349537 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumors, NSCLC, Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07349537?
The interventions under investigation include: RMC-5127 (DRUG), daraxonrasib (DRUG), cetuximab (DRUG).
Who is sponsoring clinical trial NCT07349537?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07349537 being conducted?
This trial has 5 study locations across Michigan, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07349537's enrollment target sits among peer trials
574 24th of 278 higher than 255 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- NCT05919264 · 575 participants · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- NCT06583148 · 575 participants · NA
A Smoke-Free Home Intervention in Tribal Communities
- NCT06883175 · 575 participants · NA
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI